Human bone marrow-derived CD34+ cells were analyzed for the expression of the p1-family of integrin adhesion molecules. lntegrin a&l was consistently expressed by greater than 90% of CD34+ cells, including essentially all assayable granulocyte-macrophage colony-forming cells (CFU-GM) and erythroid bursts (BFU-E) as shown by fluorescence-activated cell sorting studies. Adhesion of highly enriched CD34+ cells to cultured allogeneic marrow stromal cells was largely inhibited both by monoclonal antibody to a & and to vascular cell adhesion molecule-1 (VCAM-1). a ligand for qpl.
Human bone marrow-derived CD34+ cells were analyzed for the expression of the p1-family of integrin adhesion molecules. lntegrin a&l was consistently expressed by greater than 90% of CD34+ cells, including essentially all assayable granulocyte-macrophage colony-forming cells (CFU-GM) and erythroid bursts (BFU-E) as shown by fluorescence-activated cell sorting studies. Adhesion of highly enriched CD34+ cells to cultured allogeneic marrow stromal cells was largely inhibited both by monoclonal antibody to a & and to vascular cell adhesion molecule-1 (VCAM-1). a ligand for qpl.
VCAM-1 was found to be expressed by bone marrow stromal elements in vitro both constitutively at low level and at high levels after treatment with cytokines. Induction of VCAM-1 HE DEVELOPMENT of hematopoietic cells within T the bone marrow (BM) occurs in intimate association with cells of the BM microenvironment.1,2 This phenotypically diverse population of connective tissue-type cells includes fibroblasts, adipocytes, smooth muscle cells, and endothelial cells and, collectively, represents the stromal tissue of the BM.3 Studies in vitro using the long-term BM culture (LTBMC) system have firmly established the importance of the BM stromal elements in promoting the proliferation and differentiation of hematopoietic cell^.^,^ While the production and release of various cytokines represents one aspect of hematopoietic regulation by the ~t r o m a ,~,~ it is clear that cellular interactions, both cell-cell and cell-extracellular matrix (ECM), between hematopoietic cells and stromal cells are also of major importance.2,8-1° Such adhesive interactions are believed to be responsible for the "homing" of hematopoietic stem cells to the marrow after marrow transplantation. In normal steadystate hematopoiesis, these adhesion events probably function both to retain primitive progenitor cells within the marrow and to regulate the organized development and release of their mature progeny from the marrow."
In the last 5 years there has been a considerable increase in our understanding of the mechanisms that regulate cell adhesion in multicellular organisms. These advances have occurred as a result of the identification and characterization of a wide variety of cell surface molecules that function was cytokine-and time-dependent with maximum levels being obtained after 4 hours of exposure to a combination of interleukin-4 and tumor necrosis factor-Cytokine-induced stromal cells bound threefold higher numbers of CFU-GM and BFU-E, this increase being abrogated by anti-cqp, and anti-VCAM-1 antibodies. In addition, the adhesion to stroma of more immature progenitors, the long-term culture initiating cells, also occurred through an a&1 /VCAM-l-dependent mechanism. These studies identify an adhesion mechanism of potential importance in the localization of primitive progenitors within the hematopoietic microenvironment.
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as adhesion receptors for specific ligands.12-15 One such class of molecules, known as integrins, is a large family of integral membrane glycoproteins comprising at least 15 ctp heterodimers that mediate both cell-cell and cell-ECM interactions and play important roles in a wide variety of cellular functions ranging from embryonic development to the regulation of T-cell immune response^.'^-'^ The integrin subfamily is defined by the common p1 subunit associated with any one of 6 a chains and includes receptors for the ECM components fibronectin, laminin, and collagen.l2-I8 p1 integrins have well-documented patterns of expression on peripheral blood leukocyte^,^^-^^ but relatively little is known of their expression on BM marrow cells and less still on hematopoietic progenitor cells.
In the present study, we show that primitive hematopoietic progenitor cells express high levels of integrin a&. Furthermore, we show that mediates the binding of these cells to vascular cell adhesion molecule-1 (VCAM-1) expressed both constitutively and inducibly by BM stromal cells.
MATERIALS AND METHODS
BM cells and cell separation. BM cells were obtained from normal donors after informed consent as defined by the Internal Review Board at the Fred Hutchinson Cancer Research Center. To obtain a mononuclear cell fraction, cells were separated over Ficoll (Lymphoprep, Nygaard, Oslo). BM cells highly enriched in CD34+ cells were prepared by column immunoadsorption using monoclonal antibody (MoAb) 12.8,19 as previously described.z0 In all experiments, the frequency of CD34+ cells in the enriched fraction was greater than 75% as determined by flow cytometric analysis.
Antibody reagents and fluorescence-activated cell sorting (FACS). MoAb 12.8 (anti-CD34; IgM) was used as a high performance liquid chromatography (HPLC)-purified Ig preparation at a final concentration of 25 kg/mL. MoAbs 163H.lR1 (anti-integrin a&; IgG1) and 6G10 (anti-VCAM-1; IgG1)21 were purified using protein A-sepharose and used at final concentrations of 20 pg/mL for both flow cytometric analysis and adhesion assays. BM stromal cell layers comprising a heterogeneous mixture of cell types, including adipocytes, fibroblasts, and smooth muscle cells, were established using cells expressing the stromal cell-specific antigen STRO-lU isolated by FACS. Cultures were maintained and passaged in IMDM supplemented with 12.5% FCS, 12.5% horse serum (Flow, McLean, VA), and 1 pmol/L hydrocortisone (Sigma, St Louis, MO) as des~ribed.~3 To study the induction of VCAM-1 expression on stromal cells, 2 x 10'' STRO-I+ cells in 200 pL of the above medium were plated in each well of a 96-well plate and allowed to adhere overnight. The cells were then incubated for various times with purified recombinant human interleukin-lp (IL-1p; 1 ng/ mL), IL-4, or tumor necrosis factor a (TNFa; both at 10 ng/mL; all factors supplied by Immunex Corp, Seattle, WA), either singly or in combinations. Expression of VCAM-1 was assessed by incubating the cells with anti-VCAM-1 MoAb 6G10 or with an isotypematched MoAb of irrelevant specificity followed sequentially by rabbit antimouse IgG and 1251-protein A (105 cpm). After washing, the cells were solubilized in 1% sodium dodecyl sulfate (SDS) and counted in a gamma scintillation counter (Beckman, Wakefield, MA). Immunofluorescence staining for VCAM-1 was performed according to standard techniques on stromal cell cultures established in 8-chamber slide cultures (Nunc, Naperville, IL) with or without cytokine treatment as described above. The stained cells were examined using a scanning confocal laser microscope (BioRad, Richmond, CA).
STRO-l+ stromal cell cultures were grown to confluency (approximately 2 x 105 cells/well) in 6-well plates (Costar, Cambridge, MA) and surface labeled with lZIprotein in situ according to the procedure of Kessler.% Briefly, after washing with phosphate-buffered saline (PBS), 0.8 mL of PBS was added per well containing lZI-protein (0.2 mCi/mL; NEN, Adhesion assays. Binding of immature hematopoietic cells to stromal elements was assessed by plating 10,000 plastic nonadherent CD34+ cells in 0.5 mL RPMI-1640 medium containing 5% FCS over confluent layers of stromal cells in 24-well tissue culture plates. After 2 hours of incubation at 3TC, the medium was aspirated, the plates washed twice with medium, and the cells fixed using 1% glutaraldehyde in PBS. To assess the role of and VCAM-1 in the adhesion of CD34+ cells to stromal cells, MoAbs 163H.lR1 and 6G10 were added at the commencement of the adhesion assays at a final concentration of 20 p,g/mL. Peptide EILDVPST, corresponding to the amino acid sequence bound by a& in the CS-1 domain of the alternatively spliced I11 CS region of human fibrone~tin,2~.~ and an inactive control peptide (LVTEP-SID) were synthesized. Purified peptides were dissolved in RPMI 1640 with 2% BSA and used at a final concentration of 250 pg to 1 mg/mL in all adhesion assays. In some experiments, assays were performed in the presence of a 40-Kd a-chymotrypsin fragment of fibronectin containing the heparin-binding domain (Telios Pharmaceuticals, Inc) at a final concentration of 200 pg/mL. Quantitation of adhesion was achieved by counting the number of adherent cells in 5 randomly selected fields. All assays were performed in triplicate. In some experiments, the binding assay was performed using CD34+ cells labeled with 100 pCisl. In these assays, adhesion was measured by solubilizing the adherent contents of the well in 1% SDS and counting in a gamma scintillation counter (Beckman).
To investigate the role of a&/VCAM-l pair in the binding of clonogenic BM progenitors (CFU-GM and BFU-E) and the more primitive long-term culture initiating cells (LTCIC)," experiments were performed using the coverslip transfer technique of Tsai et aLZ8 Briefly, confluent stromal cell layers were generated using STRO-1+ stromal cells on sterile 12-mm diameter glass coverslips.
Four hours before use, a proportion of the cells were treated with a combination of IL-4 and TNFa to induce high-level VCAM-1 expression and the remainder were left as uninduced controls. Adhesion assays were performed in triplicate using 1oQ CD34+ cells (105/mL in RPMI, 5% FCS) isolated by FACS (per coverslip in the presence of medium alone), isotype-matched control MoAb, and MoAbs 163H.lR1 and 6G10 (individually and in combination) at a final concentration of 20 pg/mL. After 2 hours of incubation at 37T, the coverslips were washed with warm IMDM/20% FCS to remove nonadherent cells, and the latter cells collected and assayed in triplicate in methylcellulose-containing medium as described above. Stroma-adherent progenitors were assayed by transferring each coverslip to a 35-mm dish and overlaying with 2 mL of methylcellulose culture medium.
The role of q p l and VCAM-1 in the binding of LTCIC to stromal cell layers was investigated using adhesion assays identical to those described above with the following exceptions. Firstly, 5 x 103 CD34+ cells isolated by FACS on the basis of Rhodamine 123 (CD34+ Rh123DULL) were transferred to each coverslip to provide an enriched population of LTCIC.29*30 Secondly, stroma adherent progenitors remaining after washing were assayed for LTCIC by transferring individual coverslips to 35-mm dishes and overlaying with LTC medium. Cultures were fed weekly by demidepopulation and assayed for their production of clonogenic cells as described?l
RESULTS
To investigate the potential role of p1 integrins in mediating progenitor cell-stromal cell adhesion, BM mononuclear cells were stained by indirect immunofluorescence using a panel of MoAbs to specific integrin heterodimers. With MoAbs to integrins OL$I and a3p1 we observed binding to only small numbers of BMC (15) . However, MoAb 163H.lR1, specific for a&, reacted with 40% to
Integrin a& -PE 50% of BMC. Significantly, 163H bound to approximately 90% of cells expressing CD34 (Fig l) , an antigen expressed by 1% to 4% of BMC, including all assayable committed progenitor cells and primitive stem cells capable of repopulating the hematopoietic system after marrow transplantation.19,z9.32 Dual-color FACS showed that 100% of granulocyte-macrophage colony-forming cells (CFU-GM) and 2 90% of erythroid progenitors (BFU-E) were recovered in the population of cells with the phenotype CD34+/c&-population (Table 1) .
has been shown to mediate binding of cells to two distinct proteins, fibronectin, a component of the ECM, and VCAM-1, an integral membrane glycoprotein expressed by cytokine-activated endothelial ~e l l s . 3~~~ Fibronectin is a well-documented component of the ECM synthesized by BM stromal cells and has been shown to support the adhesion of BFU-E.28,35 However, data from preliminary experiments showed that the binding of purified CD34+ cells to stromal cell layers, while efficiently blocked by MoAb 163H, was unaffected by a polyclonal rabbit antiserum to human fibronectin (data not shown), suggesting that q p l was binding to a ligand other than fibronectin. We therefore investigated whether cultured human BM stromal cells expressed VCAM-1, either constiTo date, (Fig 2A  and B) and a radioimmunobinding assay using MoAb 6G10 to VCAM-1 (Fig 2C) . After treatment of the stromal cells with either IL-lp, IL-4, or TNFa, there was a rapid increase in the expression of VCAM-1 that reached maximal levels between 4 and 24 hours after the addition of cytokines. Various combinations of these cytokines were used, but only IL-4 + TNFa resulted in increased levels of VCAM-1 expression over that obtained with the individual factors during this time period.
To identify the molecular species identified by MoAb 6G10 on the cytokine-treated stromal cells, we analyzed the cell surface molecules identified by 6G10 on stromal cells after overnight culture with IL-4 + TNFa. Shown in Fig 2D is an SDS-PAGE analysis demonstrating specific immunoprecipitation of a 130-Kd moiety from the stromal cells. on CD34+ cells and the inducible expression of a potential ligand, VCAM-1, on marrow stromal elements, we next addressed whether these molecules could mediate cell adhesion of hematopoietic progenitors to BM stroma. Adhesion assays were performed using CD34+ cells puri- Because not all CD34+ cells have hematopoietic precursor activity, we conducted a parallel series of experiments to assess the proportion of hematopoietic progenitors within the CD34+ population that adhered to the stromal cells under these various conditions (Fig 4) . As observed with the CD34+ cells, cytokine treatment of the stromal layer resulted in a significant increase in the proportion of CFU-GM and BFU-E in the input population that were adherent. 163H.lR1 or 6G10 inhibited the adhesion of both classes of progenitors to cytokine-treated stromal cells by up to 90% relative to that seen with isotype-matched control MoAbs. Significantly, 6G10 also effectively blocked binding of progenitors to uninduced stromal cells, suggesting constitutive expression of VCAM-1 by components of the adherent cell layer in LTBMC. A minor role for integrin a&-fibronectin-mediated interactions was observed in assays performed using uninduced stromal layers in which a 40-Kd a-chymotrypsin fibronectin fragment containing the heparin binding domain and a synthetic peptide EILD-VPST both partially blocked BFU-E adhesion to the stromal cell layer but were significantly less effective in blocking the binding of CFU-GM. However, with cytokinetreated stromal cells, these reagents showed a greatly reduced ability to inhibit progenitor cell adhesion, significantly less so than anti-VCAM-1 or a & MoAbs (Fig 4) . strated high-level expression of integrin by all CD34+/ Rh123DULL cells (Fig 5A) , suggesting the likelihood that LTCIC would also be a&+. To examine this, CD34+/ Rh123DULL cells isolated by FACS were incubated on cytokine (TNFcc or IL-4)-induced allogeneic stromal cell layers derived from STRO-1+ cells in the presence of saturating concentrations of 163H, 6G10, or isotype control MoAb. After 2 hours, all nonadherent cells were removed by thorough washing, and the cultures were overlaid with fresh LTC medium and assayed for their production of clonogenic progenitors for the following 8 weeks. As shown in Fig 5B, virtually all LTCIC bound avidly to the stromal cell layer during the 2 hours of incubation, as indicated by the sustained production of progenitor cells over the ensuing weeks. In contrast, assays performed in the presence of either 163H or 6G10 resulted in a marked suppression of the onset and longevity of hematopoiesis in LT-BMC. This was shown to be due to blocking of adhesion and not to any nonspecific toxic effect on LTCIC because cells remaining nonadherent after assay in the presence of 6G10 were able to initiate hematopoiesis when transferred to other stromal cell layers.
Having demonstrated the presence of integrin

DISCUSSION
In these studies we have examined the nature of the adhesive interactions that occur between primitive human hematopoietic progenitors and the stromal elements of the BM. The results presented here clearly show that human BM progenitors (CFU-GM and BFU-E) and the more primitive LTCIC express integrin and use this adhesion receptor to bind to BM stromal cells through interaction with VCAM-1. Integrin a& is expressed by a wide variety of circulating lymphoid and myeloid ce11s17,26,36*37 and functions as a receptor for both fibronectin and VCAM-l.25,26,33,M The sites on involved in interaction with fibronectin are distinct from those involved in binding to VCAM-l.= On the fibronectin molecule, qpl recognizes an amino acid sequence GPEILDVPST that is present within the CS-1 domain of the alternatively spliced I11 CS region.25s26 The site on the VCAM-1 molecule that interacts with has yet to be defined. Fibronectin is a major component of the ECM synthesized by BM stromal cells in vitro and has been shown to promote the adhesion of murine colony-forming unit spleen cells (CFU-S), BFU-E, and LTCIC,28,35,39,40 but not CFU-GM. 28, 35 In agreement with these observations, the adhesion of BFU-E to stromal cell layers was partially inhibited both by a synthetic fibronectin peptide containing the binding site for and by a 40-Kd a-chymotrypsin fragment of fibronectin containing the same sequence, thereby demonstrating a role for in mediating attachment to fibronectin. However, anti-wpl MoAb resulted in a very large inhibition of both BFU-E and CFU-GM adhesion. Because the adhesion of CFU-GM was largely unaffected by EILDVPST peptide, these data suggested that a & was also interacting with a ligand other than fibronectin. This alternative ligand was shown to be VCAM-1, as demonstrated by the marked inhibition of adhesion of BFU-E and CFU-GM that occurred in the presence of anti-VCAM-1 antibody.
CFU-GM
VCAM-1 or INCAM-110 has been described on vascular endothelial cells after treatment with inflammatory mediators,33,34,38s41 and although its precise physiologic role remains to be defined, VCAM-1 has been suggested to play a role in leukocyte extravasation at sites of inflammation, retention of lymphocytes in germinal centers, atherogenesis, and in tumor m e t a~t a s i s . 3~,~~,~~ VCAM-1 expression has been reported on several nonvascular cell types such as tissue macrophages and dendritic cells.42~u We now show that the fibroblastic stromal cell elements of the BM also express VCAM-1. Expression of VCAM-1 on stromal cells was upregulated by IL-1, IL-4, and TNFa, the same cytokines that have previously been shown to induce VCAM-1 on vascular endothelial ~e l l s . 2 * -~~,~ Notably, the molecular weight of the glycoproteins immunoprecipitated by 6G10 was 130 Kd, some 20 Kd larger than that of VCAM-1 expressed by endothelial cells of human and primate 0rigin.2~~~~ This finding may reflect selective expression by BM stroma of the recently identified VCAM-1 in a form that incorporates an additional seventh domain in its extracellular p0rtion.4~ We also found evidence of constitutive expression of VCAM-1 by marrow stromal elements in vitro, suggesting that this adhesion mechanism may be important in both normal (steady state) and stimulated hematopoiesis such as occurs in inflammatory states or after BM transplantation. In agreement with these findings, Miyake et a146,47 and Kina et a P have recently reported a similar adhesion mechanism between murine lymphoid precursor cells and stromal cells derived from the thymus and BM mediated by a 100-to 107-Kd glycoprotein on the stromal cells. In addition, Ryan et a1 have recently demonstrated that adhesion of early human B-lymphocyte precursors to BM stromal cells also occurs through an a&/VCAM-1-mediated me~hanism.4~
The molecular basis of cell adhesion of primitive hematopoietic progenitors to the BM stroma is clearly a complex phenomenon. A wide variety of adhesion molecules in addition to have been described in CD34+ cells, including CD44: O CD54;l and LFA-1.52 Others have described interactions involving stromal cell-derived ECM proteins such as hemonectid3 and proteoglycansS4 or cellcell interaction mediated by endogenous le~tins.5~ In the current study, it is significant that we were unable to completely block the binding of hematopoietic progenitors using either a combination of anti-qpl and anti-VCAM-1 antibodies (Fig 4) or using this antibody pair together with EILDVPST peptide to investigate the role of fibronectin in this setting. The latter combination of reagents was no more efficient at inhibiting adhesion than the two-antibody combination alone (data not shown). While these experiments do not definitely exclude a role for fibronectin in these adhesive interactions, our interpretation of these data is that the potential role of fibronectin is relatively minor compared with that of VCAM-1. Moreover, the failure to completely abrogate binding with these reagents might indicate a role for other adhesion molecules in this setting. Expression by progenitors of any array of adhesion molecules with different ligand specificities might be anticipated given both the heterogeneity of stromal elements within the BM microenvironment with which progenitor cells may interact, including both fibroblastic and endothelial cell^,^,^^^ and the potential complexity of the phenomenon of stem cell homing to the marrow after either endogenous migration or BM t r a n~p l a n t a t i o n .~~,~~ The data presented here suggest that the a&/VCAM-l interaction may promote the homing or attachment of primitive hematopoietic cells within the marrow after transplantation. The analogous role of an a4-containing integrin as a homing receptor on lymphocytes for gut-associated lymphoid tissue is well d o c~m e n t e d .~~ Reciprocally, because mature hematopoietic cells such as granulocytes and erythrocytes lose expression of q P 1 as they develop, the qP1/VCAM-l interaction may also serve to regulate the release of mature hematopoietic cells from the marrow. We are currently investigating these possibilities.
